UCB PHARMA SA
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
New Global Review Reveals Comprehensive Landscape of Interstitial Cystitis Clinical Trials in 2025
A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide.
NHS Approves Fenfluramine for Children with Lennox-Gastaut Syndrome, Offering New Hope for Severe Epilepsy Treatment
The NHS has approved fenfluramine, the first non-cannabis based treatment for Lennox-Gastaut syndrome (LGS), offering new hope for children aged 2 and above with this severe form of epilepsy.
UCB Pharma Eyes Further Expansion in South Korea Following Recent Drug Approvals
UCB Pharma aims to expand its portfolio in South Korea after securing approvals for Bimzelx (bimekizumab) for plaque psoriasis and Zilbrysq (zilucoplan) for myasthenia gravis.
Bimekizumab Approved by FDA for Moderate to Severe Hidradenitis Suppurativa
The FDA has approved bimekizumab (Bimzelx; UCB Pharma) for treating moderate to severe hidradenitis suppurativa in adults, marking its fifth approved indication in the US.
FDA Approves Bimekizumab (Bimzelx) for Moderate-to-Severe Hidradenitis Suppurativa
The FDA has approved bimekizumab-bkzx (Bimzelx) for treating moderate-to-severe hidradenitis suppurativa (HS) in adult patients, addressing a significant unmet clinical need.
UCB's Bepranemab Shows Promise in Reducing Tau Tangles in Alzheimer's Subgroup
Bepranemab, a monoclonal antibody from UCB Pharma, is the first to demonstrate a slowing of tau tangle accumulation in Alzheimer's patients, marking a potential shift in treatment strategies.
Certolizumab Pegol Reduces Inflammation in axSpA but Clinical Improvement Varies
A post hoc analysis of the RAPID-axSpA trial showed certolizumab pegol (CZP) significantly reduced inflammation in patients with axial spondyloarthritis (axSpA).
Rozanolixizumab Shows Efficacy in Older Adults with Generalized Myasthenia Gravis
A post-hoc analysis of the Phase 3 MycarinG study reveals rozanolixizumab's efficacy in treating generalized myasthenia gravis (gMG) in patients aged 65 and older.